Investment Analysts’ price target changes for Monday, May 14th:
Amtrust Financial Services, Inc. (NASDAQ: AFSI) had its price target raised by analysts at FBR Capital from $32.00 to $35.00. They now have an “outperform” rating on the stock.
Allstate (NYSE: ALL) had its price target raised by analysts at FBR Capital from $35.00 to $40.00. They now have an “outperform” rating on the stock.
Alere Inc (NYSE: ALR) had its price target lowered by analysts at Wedbush to $23.00.
Ariad Pharmaceutical (NASDAQ: ARIA) had its price target raised by analysts at Summer Street Research from $16.00 to $21.00. They now have a “buy” rating on the stock.
Ariad Pharmaceutical (NASDAQ: ARIA) had its price target raised by analysts at Summer Street to $21.00.
Aruba Networks, Inc. (NASDAQ: ARUN) had its price target lowered by analysts at Mizuho from $23.00 to $18.00. They now have a “neutral” rating on the stock.
ATP Oil & Gas Co. (NASDAQ: ATPG) had its price target lowered by analysts at Pritchard Capital to $10.00.
Breitburn Energy (NASDAQ: BBEP) had its price target raised by analysts at Citigroup from $26.00 to $27.00.
Biomarin Pharm (NASDAQ: BMRN) had its price target raised by analysts at Citigroup from $45.00 to $49.00.
Career Education Corp. (NASDAQ: CECO) had its price target lowered by analysts at Bank of America from $7.00 to $6.50.
Chesapeake Energy (NYSE: CHK) had its price target lowered by analysts at Stifel Nicolaus from $29.00 to $25.00. They now have a “buy” rating on the stock.
Chesapeake Energy (NYSE: CHK) had its price target lowered by analysts at JPMorgan Chase from $15.50 to $10.00.
Chesapeake Midstream Partners LP (NASDAQ: CHKM) had its price target lowered by analysts at Ladenburg Thalmann to $37.00.
Dangdang (NASDAQ: DANG) had its price target lowered by analysts at Credit Suisse from $10.40 to $9.60.
Walt Disney (NYSE: DIS) had its price target raised by analysts at Stifel Nicolaus to $50.00.
Finisar (NASDAQ: FNSR) had its price target lowered by analysts at Stifel Nicolaus to $22.00.
Full Circle Capital (NASDAQ: FULL) had its price target lowered by analysts at Ladenburg Thalmann from $8.00 to $7.50.
Furiex Pharmaceuticals Inc (NASDAQ: FURX) had its price target raised by analysts at Ladenburg Thalmann from $28.00 to $33.00. They now have a “buy” rating on the stock.
IAMGOLD Corp (NYSE: IAG) had its price target lowered by analysts at Stifel Nicolaus to $18.00.
McDermott International (NYSE: MDR) had its price target lowered by analysts at Citigroup from $19.00 to $18.00.
McDermott International (NYSE: MDR) had its price target lowered by analysts at Goldman Sachs from $15.00 to $14.00.
Medivation Inc (NASDAQ: MDVN) had its price target raised by analysts at Citigroup from $90.00 to $129.00.
McCormick (NYSE: MKC) had its price target raised by analysts at Deutsche Bank from $56.00 to $59.00.
Medicis Pharmaceutic (NYSE: MRX) had its price target raised by analysts at Jefferies Group to $49.00.
Targa Resources Partners (NASDAQ: NGLS) had its price target raised by analysts at Bank of America from $44.00 to $46.00.
NetApp Inc. (NASDAQ: NTAP) had its price target lowered by analysts at Piper Jaffray from $53.00 to $49.00.
NVIDIA (NASDAQ: NVDA) had its price target lowered by analysts at Jefferies Group to $15.00.
Prospect Capital (NASDAQ: PSEC) had its price target raised by analysts at Ladenburg Thalmann from $11.00 to $11.50.
Renewable Energy Group Inc (NASDAQ: REGI) had its price target lowered by analysts at Canaccord Genuity from $13.00 to $12.00.
Sagent Pharmaceuticals Inc (NASDAQ: SGNT) had its price target lowered by analysts at Morgan Stanley to $27.00.
Synchronoss Technologies, Inc. (NASDAQ: SNCR) had its price target lowered by analysts at Goldman Sachs from $37.00 to $28.00.
AT&T Inc. (NYSE: T) had its price target raised by analysts at Canaccord Genuity from $32.00 to $35.00. They now have a “buy” rating on the stock.
Tornier BV (NASDAQ: TRNX) had its price target lowered by analysts at Piper Jaffray from $26.00 to $24.00.
Verizon (NYSE: VZ) had its price target raised by analysts at Canaccord Genuity from $36.00 to $41.00. They now have a “buy” rating on the stock.
WuXi PharmaTech (NYSE: WX) had its price target raised by analysts at Deutsche Bank from $16.00 to $17.00.